BIOARRAY EARLY DIAGNOSED BREAST CANCER CASES IN THE SCIENCE PARK OF THE SPANISH UNIVERSITY MIGUEL HERNANDEZ UMH
The company located in the Science Park of the UMH, Bioarray, has been able to carry out since 2010 approximately 50% of positive diagnoses in patients with breast cancer. Also, Bioarray has managed to identify about 30% of somatic mutations in susceptible patients of colorectal cancer. So that the rate of diagnosis with positive result of leukemia has reached 60.
What Bioarray test are that early diagnosed breast cancer cases?
The technique employed by the company Bioarray is characterized by amassive gene sequence that possibly reach beforehand to determine the probability of breast cancer. It is, therefore, of key information with the possibility of making a correct medical follow-up when controlling health and allow the prevention of future cancers.
Conventional sequencing of genes developed by the Bioarray, located in the campus of the University Miguel Hernández of Elche (Spain) UMH, focuses on a series of biochemical technology and methods used to define the order of nucleotides in DNA. In a short time, Bioarray has also employed high-performance sequencing techniques, known as next generation sequencing. This technique is characterized by parallelize many sequencing operations at the same time, so that it is able to reduce costs and simplify work methods employed.
What good is knowing the sequence of genes according to Bioarray?
What is basic in the gene sequence is to have within reach inheritable genetic information, i.e., a whole series of changes that can be transferred and increase the probability or risk that a person can become a disease such as cancer. Knowing that mutations can be inherited, that does not involve all the seed receives it or experience it. As it suggests Vanessa Penacho, main responsible of ID’s Bioarray: “cancer is not inherited, but that what is transferred is somatic mutations susceptible to developing the disease”.
By this fact, it is key to make follow-ups to be able detecting cancer early. “Cancer, along with neurodegenerative diseases, are two of the most serious health problems in society. For this reason, it is necessary to have them controlled and tracking to minimize their risks”, in words of Vanessa Penacho.
At the same time, according to different statistics, it is estimated that you close of between 5% and 10% mutations that inherit carry out a key role in the future occurrence of cancers.
What Bioarray contributions are at the Technological Park of the University Miguel Hernández of Elche UMH?
Bioarray will develop a study of the liquid biopsy. The method less invasive for the human being that known traditional biopsy, makes it possible to identify cancer cells and DNA circulating tumor through a simple blood test. This technique has been carrying out slowly in Spain, and it represents a qualitative leap forward in the fight against cancer, being faster, not only in the diagnosis, but also in the treatment.